Skip to main content
Research project

Cragg. LLR. 12050. Optimising antibody therapy for Lymphoma.


Lead researcher

Professor Mark Cragg

Professor in Experimental Cancer Biology

Research interests

  • Antibody biology
  • Antibody engineering
  • Cancer Immunotherapy
Other researchers

Professor Stephen Beers

Professor of Immunology & Immunotherapy

Research interests

  • Edit
  • Antibody Effector Functions Monoclonal antibodies (mAb) have become established in the treatment of a variety of malignancies - transforming patient outcomes. Despite this undoubted impact, responses remain variable and their mechanisms of action and of tumour resistance are controversial. Our research is focussed on understanding these complex processes using a variety of complementary models and systems to better inform antibody selection, design and clinical application.
  • Current research interests:

Professor Jon Strefford PhD

Head of School

Professor Peter Johnson CBE MD FRCP FMedSci

Professor of Medical Oncology

Collaborating research institutes, centres and groups

Back to top